|
|
|
|
Vol. 303, Issue 1, 211-217, October 2002
Department of Psychiatry, University of Mississippi Medical Center,
Jackson, Mississippi (W.L.W., R.R., Z.W., G.A.O., I.A.P.); and
Departments of Neurology and Pharmacology, Georgetown University
Medical Center, Washington, DC (P.P., A.K.)
Drugs that block dopamine uptake often function as positive
reinforcers but can differ along the dimension of strength or effectiveness as a positive reinforcer. The present study was designed
to examine pharmacological mechanisms that might contribute to
differences in reinforcing strength between the piperidine-based cocaine analog (+)-methyl
4
-(4-chlorophenyl)-1-methylpiperidine-3-
-carboxylate [(+)-CPCA] and cocaine. Drugs were made available to rhesus monkeys (n = 5) for i.v. self-administration under a
progressive ratio schedule. Both compounds maintained responding with
sigmoidal or biphasic dose-response functions (0.1-1.0
mg/kg/injection). (+)-CPCA was one-fourth as potent as cocaine and
maintained fewer injections per session, at maximum. For in vitro
binding in monkey brain tissue, (+)-CPCA was about one-half as potent
as cocaine at the dopamine transporter (DAT), and the two compounds had
similar affinities at the norepinephrine transporter. (+)-CPCA was less than 1/10 as potent as cocaine at the serotonin transporter. In ex vivo
binding in rat striatum, occupancy of the DAT increased directly with
dose to a maximum of approximately 80% for both compounds, and
(+)-CPCA was about one-fourth as potent as cocaine. Ex vivo DAT
occupancy was significantly higher for cocaine than (+)-CPCA at 2 min
after injection but similar at other times. Thus, the primary
differences between these compounds were in serotonin transporter
affinity and the kinetics of DAT binding. These results suggest that
(+)-CPCA is a weaker positive reinforcer than cocaine because it has a
slower onset of action over the first few minutes after i.v. injection.
This article has been cited by other articles:
![]() |
T. Hiranita, P. L. Soto, A. H. Newman, and J. L. Katz Assessment of Reinforcing Effects of Benztropine Analogs and Their Effects on Cocaine Self-Administration in Rats: Comparisons with Monoamine Uptake Inhibitors J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 677 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. T. Ukairo, C. D. Bondi, A. H. Newman, S. S. Kulkarni, A. P. Kozikowski, S. Pan, and C. K. Surratt Recognition of Benztropine by the Dopamine Transporter (DAT) Differs from That of the Classical Dopamine Uptake Inhibitors Cocaine, Methylphenidate, and Mazindol as a Function of a DAT Transmembrane 1 Aspartic Acid Residue J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 575 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Lile, Z. Wang, W. L. Woolverton, J. E. France, T. C. Gregg, H. M. L. Davies, and M. A. Nader The Reinforcing Efficacy of Psychostimulants in Rhesus Monkeys: The Role of Pharmacokinetics and Pharmacodynamics J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 356 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Kozikowski, K. M. Johnson, O. Deschaux, B. C. Bandyopadhyay, G. L. Araldi, G. Carmona, P. Munzar, M. P. Smith, R. L. Balster, P. M. Beardsley, et al. Mixed Cocaine Agonist/Antagonist Properties of (+)-Methyl 4beta -(4-Chlorophenyl)-1-methylpiperidine-3alpha -carboxylate, a Piperidine-Based Analog of Cocaine J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 143 - 150. [Abstract] [Full Text] |
||||